The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short
course of LMWH) compared with dalteparin for the prevention of the combined outcome of
recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with
cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will
be compared with dalteparin for superiority.